Investigating the basis of sexual dysfunction during late-onset hypogonadism

Tharakan, Tharu; Miah, Saiful; Jayasena, Channa N.

doi:10.12688/f1000research.16561.1

Cited by 8 publications

(7 citation statements)

References 101 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…14 FH has recently come under greater scrutiny with the widespread use of testosterone therapy (TTh), and concerns regarding the efficacy and safety of TTh have been raised. 15 TTh may exert several benefits with regard to metabolic profile, body composition, psychological, and sexual parameters. Multiple studies have shown that TTh applied to obese men with FH and T2D improves glycemic control; reduces insulin resistance (IR), inflammation, and symptoms of hypogonadism; increases bone mineral density; and improves vascular function and morphology along with improvements in cognitive function.…”

Section: Introductionmentioning

confidence: 99%

Effects of Testosterone Therapy on Erythrocytosis and Prostate Adverse Events in Obese Males with Functional Hypogonadism and Type 2 Diabetes in a 2-Year Clinical Trial

Antonič

Antonič²,

Pfeifer

2020

Androgens: Clinical Research and Therapeutics

View full text Add to dashboard Cite

Aims: Testosterone therapy (TTh) has been postulated to increase the risk of prostate adverse events (PAEs) and erythrocytosis, risk further exacerbated in high-risk obese patients with type 2 diabetes (T2D) and functional hypogonadism (FH). We investigated safety aspects of TTh in obese males with FH and T2D by observing the incidence of PAEs and erythrocytosis and determining when statistically significant difference from the baseline manifests in hematocrit (Hct) and prostate-specific antigen (PSA) levels. Materials and Methods: Fifty-five obese Caucasian men with FH and T2D participated in a two-part prospective observational clinical study (first year: double-blind randomized placebo-controlled trial employing testosterone undecanoate; second year: open-label follow-up with all participants receiving TTh). Outcomes were assessments of Hct and PSA levels at the baseline, and 3, 6, and 12 months into each of 2 years of the study. Results: No adverse cardiovascular events or PAEs were observed. Hct first increased at statistically significant level from the baseline after 3 months of TTh in group T and after 6 months of TTh in group P. Individual Hct values for all participants remained <0.52 throughout 2-year course of the study. PSA increased from the baseline in both groups within 3-6 months of trial start regardless of intervention applied (placebo or TTh). Fifty-two patients never exceeded PSA level of 4.0 lg/L nor experienced year-on-year PSA increase >1.4 lg/L. No subject ever reached supraphysiological concentration of total testosterone. Conclusions: Our results show that TTh may be safe in obese males with FH and T2D. ClinicalTrials.gov ID: NCT0379232.

show abstract

Section: Introductionmentioning

confidence: 99%

Effects of Testosterone Therapy on Erythrocytosis and Prostate Adverse Events in Obese Males with Functional Hypogonadism and Type 2 Diabetes in a 2-Year Clinical Trial

Antonič

Antonič²,

Pfeifer

2020

Androgens: Clinical Research and Therapeutics

View full text Add to dashboard Cite

show abstract

“… 59 Also, they lack specificity for HG and therefore, should be utilized after the diagnosis of HG through measurement of testosterone has been established. 8 In that regard, if symptoms persist during follow-up other pathologies must be evaluated.…”

Section: Discussionmentioning

confidence: 99%

Testosterone Replacement Therapy in the Aged Male: Monitoring Patients’ Quality of Life Utilizing Scoring Systems

Tsampoukas¹,

Pang²,

Papatsoris³

et al. 2022

IJGM

Self Cite

View full text Add to dashboard Cite

Hypogonadism has been associated with significant deterioration of well-being. In the aging male, late-onset hypogonadism affects sexual life, mental health, levels of energy, lower urinary tract symptoms and, therefore, quality of life may be found significantly deteriorated. Testosterone replacement or supplementation therapy has been found efficient to reverse the adverse effects of hypogonadism and improve quality of life. Scales and questionnaires assessing the general health, urinary symptoms, sexual health, and cognition can provide a thorough assessment of the clinical syndrome, optimize treatment, assist the follow-up, and facilitate referrals to other specialties depending on the chief complaint. A systematic assessment might combine several tools, but the optimal ones and the exact usage is unknown. In this narrative review, we are flipping through the literature presenting the available tools per domain for the assessment of quality of life in men on testosterone replacement therapy and we discuss the optimal usage.

show abstract

“…Sexuality is an important aspect of human life, and emotions related to sexual activity influence mental well-being, relationship, or how we see ourselves. Sexual function disorders (e.g., erectile dysfunction) caused by prostate carcinoma significantly reduces the quality of life of men [6][7][8]. Cancer treatment is also related to reduced sex drive and penile dysfunction manifesting itself through, for example, reduced ability to have an orgasm, erectile disorders, or urinary incontinence [9,10].…”

Section: Discussionmentioning

confidence: 99%

Sexual and Psychoemotional Disorders in Male Patients Treated for Prostate Carcinoma

Dąbrowska-Bender¹,

Słoniewski²,

Religioni³

et al. 2020

Male Reproductive Health

View full text Add to dashboard Cite

The prostate carcinoma affect the quality of life of most male patients, including in particular their sexual and emotional life. The aim of study was to assess sexual and psychoemotional disorders in male patients diagnosed with prostate carcinoma and receiving cancer treatment. The study's patients were recruited at the Oncological Hospital in Wieliszew, Poland, between September 2016 and December 2017. The study was performed in 166 male patients diagnosed with prostate cancer. Two standardized questionnaires were used in the study, EORTC QLQ-C30 and QLQ-PR25, for patients with prostate cancer, developed by the European Quality of Life Group. The type and stage of cancer treatments were a significant contributor to feeling tense, worried, depressed, and irritable among the study patients. The stage of treatment, however, caused a negative effect on these parameters. Pretreatment patients declared high or very high satisfaction with their sexual life, while posttreatment patients and those on cancer treatment indicated low sexual satisfaction. However, a feeling of embarrassment during intimate contact as well as erectile disorders correlated both with the type and stage of cancer treatment. Our results show that affected male patients should be offered continuous psychological care, especially those waiting for treatment and those on treatment.

show abstract

Investigating the basis of sexual dysfunction during late-onset hypogonadism

Cited by 8 publications

References 101 publications

Effects of Testosterone Therapy on Erythrocytosis and Prostate Adverse Events in Obese Males with Functional Hypogonadism and Type 2 Diabetes in a 2-Year Clinical Trial

Effects of Testosterone Therapy on Erythrocytosis and Prostate Adverse Events in Obese Males with Functional Hypogonadism and Type 2 Diabetes in a 2-Year Clinical Trial

Testosterone Replacement Therapy in the Aged Male: Monitoring Patients’ Quality of Life Utilizing Scoring Systems

Sexual and Psychoemotional Disorders in Male Patients Treated for Prostate Carcinoma

Contact Info

Product

Resources

About